The radiopharmaceutical lutetium 177 can be used after radium 223 to treat metastatic castration-resistant prostate cancer.

Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on Novartis AG (NOVN – Research Report) today and set a price target of ...

The company is expanding its cardiology portfolio with a new treatment for transthyretin amyloid cardiomyopathy in Europe.

The FDA approved several therapies in oncology in the month of March 2025. These drugs included treatments for ...

The antibody-drug conjugate FOR46 showed the strong potential of using CD46 as a new therapeutic target in metastatic ...

OncoHelix, a leader in precision diagnostics, is proud to announce its partnership with AstraZeneca Canada to deliver cutting-edge liquid biopsy testing for men with metastatic castration-resistant ...

Novartis’ radioligand therapy Pluvicto (lutetium Lu 177 vipivotide tetraxetan) has been approved by the US Food and Drug ...

In a report released today, Emily Field from Barclays maintained a Sell rating on Novartis AG (NOVN – Research Report), with a price target of ...

The PIK3CA wild-type cohort of the VIKTORIA-1 Phase 3 trial is on track to report topline data in Q2 2025VIKTORIA-2 Phase 3 ...

The FDA expanded the approval of Pluvicto (lutetium Lu 177 vipivotide tetraxetan) to include patients with PSMA-positive mCRPC who have been treated with ARPI therapy and are considered appropriate to ...

Novartis (NOVN: VX) announced late Friday that the US Food and Drug Administration (FDA) approved Pluvicto (lutetium Lu 177 ...

The radioligand agent is now approved for use before chemotherapy in patients who have been treated with an androgen receptor ...